

# [Cytomegalovirus infection may contribute to the reduced immune function, growth, ...](https://assignbuster.com/cytomegalovirus-infection-may-contribute-to-the-reduced-immune-function-growth-development-and-health-of-hiv-exposed-uninfected-african-children/)

[Health & Medicine](https://assignbuster.com/essay-subjects/health-n-medicine/)

## Health Problems of HIV-Exposed, Uninfected African Children

HIV-exposed, uninfected (HEU) children have always constituted the majority of children born to HIV-infected mothers, but until recently the focus has been on preventing mother-to-child HIV transmission and treating HIV-infected children, so HEU children have received little attention. Preventing mother-to-child HIV transmission remains crucial and the situation is improving with increasing provision of antiretroviral therapy (ART). As a result of decreasing infant HIV infection, the numbers of HEU children are rising and in high HIV prevalence countries of Southern Africa may account for up to 30% of births ( [1](#B1) , [2](#B2) ). Thus, any health problems HEU children experience are of immense public health importance.

Even when HIV-infected mothers are provided with ART, their HEU infants experience numerous health and development problems ( [3](#B3) ). Mortality of HEU children is increased over that of their HIV-unexposed counterparts ( [4](#B4) ). Compared with HIV-unexposed children, HEU children have lower birth weight ( [5](#B5) ), impaired early growth ( [6](#B6) ), impaired psychomotor and cognitive development ( [7](#B7) ), and immune abnormalities ( [8](#B8) ), presumably resulting from stressors during *in utero* or early postnatal life. The underlying causes of these impairments in HEU infants are probably multifactorial and include exposure to HIV itself ( [9](#B9) , [10](#B10) ), exposure to ART ( [5](#B5) ), increased exposure to infections within the household ( [11](#B11) ), and the consequences of being born into an HIV-afflicted household, with impact on socioeconomic status and child care quality ( [4](#B4) ). The relative contribution that these different factors make to the health deficits of HEU children are likely to differ in different populations and all should be addressed.

Here, we review the evidence in support of the hypothesis that one potential cause, early cytomegalovirus (CMV) infection, which appears widespread across sub-Saharan Africa, is an important contributor to impaired health and development of both HIV-infected and HEU children in many African populations, and increases the risk of postnatal HIV infection. The synergism between HIV and CMV coinfection in African adults and children has been recently reviewed ( [12](#B12) ), so this article will focus on HEU children, in particular those in Africa where the burden of both CMV and HIV infection is highest.

## Early CMV Infection among HIV-Exposed Infants

Most African infants acquire CMV infection during infancy ( [13](#B13) , [14](#B14) ). The risk of congenital CMV infection was higher among infants of HIV-infected than uninfected Zambian mothers ( [15](#B15) ). Increased infections with maternal HIV exposure could result from maternal CMV reactivation, which is common in HIV-infected women, particularly with low CD4 counts; CMV was detected in the serum and cervix of, respectively, 4. 8 and 66% ART-treated HIV-positive pregnant Kenyan women ( [16](#B16) ). Reduced placental transfer of maternal antibodies in HIV-infected women ( [8](#B8) ) may also contribute to the increased risk of early CMV infection of their infants ( [17](#B17) ). CMV infection mainly occurs in African infants during the early postnatal period and a large proportion of CMV transmission is through breastfeeding. A secondary analysis of a randomized controlled trial of breastfeeding versus formula-feeding by HIV-infected Kenyan women in the pre-ART era found that breastfeeding was associated with a significantly increased proportion of infants CMV-infected by age 1 year (89 versus 69% in the formula group), as well as earlier median acquisition of CMV infection (4. 26 versus 9. 87 months) ( [18](#B18) ). Nevertheless, as previously shown for HIV transmission in the Kenyan trial ( [19](#B19) ) as well as in other studies, breastfeeding is important for child survival and health, so switching from breastfeeding is not a feasible way to reduce transmission of CMV.

Currently, the World Health Organization recommends provision of ART during pregnancy and lactation as the best way of promoting HIV-free survival of infants ( [20](#B20) ). Although this protocol is becoming standard across Africa and is effective at decreasing HIV transmission, it does not appreciably alter the rate of African infant CMV acquisition. The rate of congenital CMV infection in South African infants did not differ according to whether their mothers had taken during pregnancy zidovudine only or triple-drug ART ( [21](#B21) ). Breast milk CMV load was similar among Malawian women who had started ART for their own health and women not on ART, even though the ART-treated women had lower plasma and milk HIV levels and both groups had similar CD4 counts ( [22](#B22) ). A recent study of American women whose ART did or did not include the protease inhibitor, nelfinavir, which has some ability to inhibit CMV replication, found no protection of nelfinavir against congenital CMV infection ( [23](#B23) ).

## Effects of Early CMV Infection on Health of HEU Children

Most concerns about CMV among non-HIV-exposed infants, particularly in the developed world, relate to congenital CMV. Congenital CMV arising from maternal primary or reactivated CMV infection during pregnancy is associated with intrauterine growth retardation and neurological, hearing, and vision impairments in the infected infant ( [24](#B24) , [25](#B25) ). In particular, 25–50% of infants diagnosed at birth with symptomatic congenital CMV (and 10% of asymptomatic congenital infections) suffer from hearing loss ( [26](#B26) ), which is often not detected until later in infancy ( [27](#B27) ). A study of CMV screening at birth for over 300 infants born to HIV-infected mothers found that, although the rates of congenital CMV infection were low (10 infants, 3%), they were higher than usually observed in HIV-unexposed infants; moreover, HEU infants with asymptomatic congenital CMV had significantly lower birth weight and lower gestational age compared with infants who were CMV-uninfected at birth ( [28](#B28) ).

Whether the early postnatal CMV infection, which is common among HEU African infants, also has adverse effects on health needs to be considered. In the pre-ART era, serum CMV in HIV-infected women at delivery was associated with almost 10-fold increase in maternal death and a fourfold increase in mortality of their HIV-infected infants by age 2 years; this remained statistically significant even after adjustment for maternal CD4 count, HIV viral load, and death ( [29](#B29) ). Early CMV infection also results in a 2. 5-fold to 4-fold increased risk of postnatal HIV infection ( [29](#B29) – [31](#B31) ), and CMV coinfection leads to more rapid infant HIV disease progression ( [29](#B29) , [32](#B32) ). It is worth noting that several reports have indicated that children of HIV-positive mothers, both infected ( [33](#B33) ) and HEU ( [34](#B34) ), are more likely than their unexposed counterparts to have impaired hearing; although other mechanisms, including exposure to HIV itself, may have contributed to deafness in these children, it could well be an indication of congenital (or even early) CMV infection that was not diagnosed at birth. Because the hearing loss associated with congenital CMV infection is often not diagnosed until later childhood (particularly at school entry), it would potentially be worth instituting formal monitoring of the hearing of HEU infants to avoid the development and educational problems often faced by children with undiagnosed deafness.

Surviving HEU children exhibit impairments including poor infant growth; ( [6](#B6) , [22](#B22) ) reduced psychomotor development; ( [7](#B7) ) and immunological abnormalities (see below). In observational studies, CMV infection was associated with poorer infant growth ( [13](#B13) , [22](#B22) ) and delayed psychomotor development ( [13](#B13) ). In a study in Malawi, breast milk CMV DNA viral load had a stronger negative association with infant growth than did milk HIV RNA load; the largest effects occurred in the first 4–6 weeks of the infant’s life, suggesting that prenatal or early postnatal exposure to CMV is key ( [22](#B22) ).

## Immunological Consequences of Early CMV Infection in HEU Infants

In older Europeans, CMV infection is associated with frailty and increased mortality, predominantly through cardiovascular disease, with an estimated 47% increased risk of death compared to uninfected people in a large UK population of people aged 65 years and over ( [35](#B35) ). CMV seropositivity in the elderly is linked with a number of immunological features that include large expansions of CMV-specific T-cells with reduced naive T-cell numbers ( [36](#B36) ), raised C-reactive protein ( [37](#B37) ), and impaired immune responses to influenza vaccination ( [38](#B38) ). In contrast, CMV is acquired very early in life in Africa, with the majority of infections occurring during infancy [85% infection at one year in a Gambian birth cohort ( [14](#B14) )]: the long-term consequences of early CMV acquisition in developing countries are not known.

The large CMV genome contains multiple genes linked with immune evasion [including the down-regulation of class I Histocompatibility Leukocyte Antigen (HLA) molecules, interference with antigen processing, suppression of T-cell proliferation, and production of a viral version of the immunosuppressive chemokine interleukin-10], which could potentially affect immune responses to other pathogens, although this has yet to be unequivocally demonstrated. Infant CMV infection is associated with profound changes in the phenotype of CD8 + and CD4 + T-cells, which show increased levels of activation and differentiation ( [39](#B39) – [41](#B41) ) similar to those described in older Europeans; however, there is no evidence of CMV-associated immune impairment in healthy infants, and vaccine responses in HIV-unexposed infants appear to be unaffected by CMV status, at least in the short term ( [42](#B42) , [43](#B43) ). The overall impact of CMV infection on vaccine responses is not well understood: in young adults, CMV infection is associated with enhanced antibody and T-cell responses to influenza vaccination ( [44](#B44) ), but in a different adult cohort CMV seropositivity was linked with reduced Natural Killer (NK) cell responses to pertussis and H1N1 influenza A antigens ( [45](#B45) ). In older adults, CMV seropositivity is associated with significantly decreased CD4 T-cell responses to influenza A core antigens ( [38](#B38) ).

Although HEU infants generally show robust vaccine responses, at least in the short term ( [46](#B46) ), CMV infection in HEU infants born to Zambian HIV-infected mothers was associated with impaired polio vaccine responses ( [47](#B47) ). The majority of the immunological perturbations described in HEU infants, including the expansion of memory T-cell subsets, reduction in naive T-cells, and heightened immune activation [reviewed in Ref. ( [8](#B8) )], are observations consistent with and potentially explained by CMV infection occurring earlier in HEU children than in the control populations studied. Few of the published studies of the immunology of HEU infants have accounted for infection with CMV [or other herpes viruses with known impact on the immune system, such as Epstein–Barr virus (EBV)].

## Impact of Maternal CMV Infection on the Placenta

As discussed earlier, it is not yet clear whether early CMV infection has an adverse effect on infant health in the absence of HIV exposure, immunosuppression, or congenital infection. Before the advent of CMV screening for infant blood transfusion, postnatal transmission of CMV to premature and low birth weight infants was associated with a range of symptoms, including fever, pneumonia, hepatosplenomegaly and hepatitis, and a high risk of death, but these children could be regarded as immunosuppressed ( [48](#B48) ). However, it may also be worth considering that some of the abnormalities described in HEU children imply that the fetus faced challenges in the prenatal environment that affected the placenta, notably the observation of marked stunting that cannot be corrected by supplementary feeding in the first year of life ( [6](#B6) ) and the reduced transfer of maternal antibodies to the infant ( [49](#B49) , [50](#B50) ), which requires an active process by the placenta in the last trimester. CMV can infect the placenta without infecting the infant, particularly in women with reactivated rather than primary CMV infection. For example, in a detailed study of the role of CMV in seven cases of intrauterine growth restriction, five were associated with CMV infection, of which three had evidence of reactivated infection and did not lead to *in utero* infection of the infant ( [24](#B24) ). Nevertheless, there was evidence of CMV proteins in placental tissue and associated pathology, such as edema and leukocyte infiltration, which suggests that CMV infection of the placenta can lead to impaired fetal growth without necessarily resulting in congenital infection. It was recently reported that CMV infection of trophoblast progenitor cells *in vitro* interferes with the early steps of the growth of placental villi and could therefore affect placental maturation and transport functions ( [51](#B51) ).

## Approaches to Decreasing Early CMV Infection of HEU Infants

Although the observational data linking early CMV infection with the poorer health and development of HEU African infants are strong, a controlled clinical trial is needed before we can assume that CMV infection causes these impairments. There is currently no ideal intervention, effective against CMV infection, safe for pregnant or lactating women and their infants, and feasible for use in Africa. A recent trial with a low dose (500 mg twice daily) of valacyclovir (GlaxoSmithKline) had no effect on the timing of infant CMV infection or breast milk CMV viral load; higher doses of the drug, as used to prevent CMV infection among transplant patients, might have had more effect but were considered unrealistic for pregnant and lactating women ( [17](#B17) ). Valganciclovir (Hoffman-La Roche) has greater anti-CMV effect than valacyclovir, has been used postnatally for congenital CMV infection ( [25](#B25) ), and led to reduced T cell activation among HIV-infected adults ( [52](#B52) ). However, a recent trial comparing 6 months versus the standard 6 weeks of valganciclovir for congenital CMV infection found side effects in a proportion of infants: 19% of infants had grade 3–4 neutropenia during the first 6 weeks of life that in three of 109 infants necessitated temporary suspension of treatment ( [25](#B25) ). A trial of hyperimmune globulin to prevent congenital CMV infection in infants of women with primary CMV infection found no significant decrease in congenital CMV infection, similar clinical outcomes among congenitally infected infants, and a higher rate of obstetric adverse events among the women treated with globulin compared to those given placebo ( [53](#B53) ).

There are a number of CMV vaccines under development [recently reviewed in Ref. ( [54](#B54) )]. These vaccines have largely been developed with the aim of preventing primary CMV infection in women of child-bearing age in developed countries. The risk of congenital CMV infection with primary infection during pregnancy is around 40%, whereas only 1–2% of already-infected women transmit CMV to their infants. Current candidate CMV vaccines predominantly aim to elicit neutralizing antibodies, using either the CMV surface glycoprotein (gB) ( [55](#B55) ), or the recently described pentameric complex (gH/gL/UL128-UL130-UL131) ( [56](#B56) ), which is required for CMV entry into epithelial cells ( [57](#B57) ). The induction of a strong, high avidity, neutralizing antibody response may also reduce congenital infection in infants of women with preexisting infection, but in HIV-infected women this could be impaired by the reduction in placental transfer of maternal antibodies that occurs during pregnancy. Other CMV candidate vaccines focus on the induction of T-cell immunity, which may have more value in controlling CMV reactivation in pregnancy and HIV infection. A phase III trial is underway in seropositive transplant recipients of a bivalent CMV DNA vaccine, expressing both gB and pp65, the main target of the T-cell response ( [58](#B58) ). In the long term, a vaccine that effectively prevents both congenital and early CMV transmission may have a major impact on the health of infants born to HIV-infected mothers in sub-Saharan Africa.

## Conclusion and Recommendations

The health and development problems of HEU infants are almost certainly multifactorial, and this review focuses on one of these factors, early CMV infection. Evidence for the potential importance of early CMV infection as a contributor to poorer outcomes in HEU infants is increasing but is not yet definitive. The field now requires a clinical trial of a safe and effective anti-CMV intervention in order to move forward. At this juncture, a trial of a currently available intervention, such as valganciclovir given to lactating women or their infants to prevent early infant infection, would be of considerable benefit in resolving these issues. If such an intervention showed proof of principle that delaying CMV infection in HEU infants benefited their health without unacceptable adverse effects, this would provide impetus for the design of safer and more efficacious CMV interventions for this large and vulnerable population. Even a safe drug would increase the already large pill burden in HIV-infected lactating women or their infants so qualitative and programmatic research would be needed to ensure that an anti-CMV treatment was acceptable as well as efficacious in relevant populations. However, there is a precedent for adding additional drugs to ART care, specifically the widespread use of prophylactic Cotrimoxazole, suggesting that an effective anti-CMV treatment could well be similarly acceptable.

## Author Contributions

SF and SRJ contributed equally to the conception and writing of this work.

## Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Funding

The authors received no funding other than their university salaries for this work.

## References

1. Shapiro RL, Lockman S. Mortality among HIV-exposed infants: the first and final frontier. *Clin Infect Dis* (2010) 50(3): 445–7. doi: 10. 1086/649887

2. Mofenson LM. New challenges in the elimination of pediatric HIV infection: the expanding population of HIV-exposed but uninfected children. *Clin Infect Dis* (2015) 60(9): 1357–60. doi: 10. 1093/cid/civ064

3. Evans C, Jones CE, Prendergast AJ. HIV-exposed, uninfected infants: new global challenges in the era of paediatric HIV elimination. *Lancet Infect Dis* (2016) 16(6): e92–107. doi: 10. 1016/S1473-3099(16)00055-4

4. Filteau S. The HIV-exposed, uninfected African child. *Trop Med Int Health* (2009) 14: 276–87. doi: 10. 1111/j. 1365-3156. 2009. 02220. x

5. Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. *J Infect Dis* (2012) 206(11): 1695–705. doi: 10. 1093/infdis/jis553

6. Filteau S, Baisley K, Chisenga M, Kasonka L, Gibson R, CIGNIS Study Team. Provision of micronutrient-fortified food from 6 months of age does not permit HIV-exposed, uninfected Zambian children to catch up in growth to HIV-unexposed children: a randomised controlled trial. *J Acquir Immune Defic Syndr* (2011) 56: 166–75. doi: 10. 1097/QAI. 0b013e318201f6c9

7. Manno D, Kowa PK, Bwalya HK, Siame J, Grantham-McGregor S, Baisley K, et al. Rich micronutrient fortification of locally produced infant food does not improve mental and motor development of Zambian infants: a randomised controlled trial. *Br J Nutr* (2012) 107(4): 556–66. doi: 10. 1017/S0007114511003217

8. Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-Jones SL. HIV-exposed uninfected children: a growing population with a vulnerable immune system? *Clin Exp Immunol* (2014) 176(1): 11–22. doi: 10. 1111/cei. 12251

9. Madhi SA, Adrian P, Cotton MF, McIntyre JA, Jean-Philippe P, Meadows S, et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. *J Infect Dis* (2010) 202(3): 355–61. doi: 10. 1086/653704

10. Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. *J Acquir Immune Defic Syndr* (2003) 33(2): 175–83. doi: 10. 1097/00126334-200306010-00010

11. Cotton MF, Slogrove A, Rabie H. Infections in HIV-exposed uninfected children with focus on sub-Saharan Africa. *Pediatr Infect Dis J* (2014) 33(10): 1085–6. doi: 10. 1097/INF. 0000000000000489

12. Adland E, Klenerman P, Goulder P, Matthews PC. Ongoing burden of disease and mortality from HIV/CMV coinfection in Africa in the antiretroviral therapy era. *Front Microbiol* (2015) 6: 1016. doi: 10. 3389/fmicb. 2015. 01016

13. Gompels UA, Larke N, Sanz-Ramos M, Bates M, Musonda K, Manno D, et al. Human cytomegalovirus infant infection adversely affects growth and development in maternally HIV-exposed and unexposed infants in Zambia. *Clin Infect Dis* (2012) 54(3): 434–42. doi: 10. 1093/cid/cir837

14. Kaye S, Miles D, Antoine P, Burny W, Ojuola B, Kaye P, et al. Virological and immunological correlates of mother-to-child transmission of cytomegalovirus in The Gambia. *J Infect Dis* (2008) 197(9): 1307–14. doi: 10. 1086/586715

15. Mwaanza N, Chilukutu L, Tembo J, Kabwe M, Musonda K, Kapasa M, et al. High rates of congenital cytomegalovirus infection linked with maternal HIV infection among neonatal admissions at a large referral center in sub-Saharan Africa. *Clin Infect Dis* (2014) 58(5): 728–35. doi: 10. 1093/cid/cit766

16. Slyker J, Farquhar C, Atkinson C, Asbjornsdottir K, Roxby A, Drake A, et al. Compartmentalized cytomegalovirus replication and transmission in the setting of maternal HIV-1 infection. *Clin Infect Dis* (2014) 58(4): 564–72. doi: 10. 1093/cid/cit727

17. Roxby AC, Atkinson C, Asbjornsdottir K, Farquhar C, Kiarie JN, Drake AL, et al. Maternal valacyclovir and infant cytomegalovirus acquisition: a randomized controlled trial among HIV-infected women. *PLoS One* (2014) 9(2): e87855. doi: 10. 1371/journal. pone. 0087855

18. Richardson BA, John-Stewart G, Atkinson C, Nduati R, Asbjornsdottir K, Boeckh M, et al. Vertical cytomegalovirus transmission from HIV-infected women randomized to formula feeding versus breastfeeding. *J Infect Dis* (2016) 213: 992–8. doi: 10. 1093/infdis/jiv515

19. Nduati R, Richardson BA, John G, Mbori-Ngacha D, Mwatha A, Ndinya-Achola J, et al. Effect of breastfeeding on mortality among HIV-1 infected women: a randomised trial. *Lancet* (2001) 357(9269): 1651–5. doi: 10. 1016/S0140-6736(00)04820-0

20. World Health Organization. *Guidelines on HIV and Infant Feeding 2010: Principles and Recommendations for Infant Feeding in the Context of HIV and a Summary of Evidence* (2010). Available from: http://www. who. int/maternal\_child\_adolescent/documents/9789241599535/en/

21. Manicklal S, van Niekerk AM, Kroon SM, Hutto C, Novak Z, Pati SK, et al. Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa. *Clin Infect Dis* (2014) 58(10): 1467–72. doi: 10. 1093/cid/ciu096

22. Meyer SA, Westreich DJ, Patel E, Ehlinger EP, Kalilani L, Lovingood RV, et al. Postnatal cytomegalovirus exposure in infants of antiretroviral-treated and untreated HIV-infected mothers. *Infect Dis Obstet Gynecol* (2014) 2014: 989721. doi: 10. 1155/2014/989721

23. Gantt S, Leister E, Jacobsen DL, Boucoiran I, Huang ML, Jerome KR, et al. Risk of congenital cytomegalovirus infection among HIV-exposed uninfected infants is not decreased by maternal nelfinavir use during pregnancy. *J Med Virol* (2016) 88(6): 1051–8. doi: 10. 1002/jmv. 24420

24. Pereira L, Petitt M, Fong A, Tsuge M, Tabata T, Fang-Hoover J, et al. Intrauterine growth restriction caused by underlying congenital cytomegalovirus infection. *J Infect Dis* (2014) 209(10): 1573–84. doi: 10. 1093/infdis/jiu019

25. Kimberlin DW, Jester PM, Sanchez PJ, Ahmed A, Arav-Boger R, Michaels MG, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. *N Engl J Med* (2015) 372(10): 933–43. doi: 10. 1056/NEJMoa1404599

26. Saigal S, Lunyk O, Larke RP, Chernesky MA. The outcome in children with congenital cytomegalovirus infection. A longitudinal follow-up study. *Am J Dis Child* (1982) 136(10): 896–901. doi: 10. 1001/archpedi. 1982. 03970460026006

27. Fowler KB, Dahle AJ, Boppana SB, Pass RF. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed? *J Pediatr* (1999) 135(1): 60–4. doi: 10. 1016/S0022-3476(99)70328-8

28. Duryea EL, Sanchez PJ, Sheffield JS, Jackson GL, Wendel GD, McElwee BS, et al. Maternal human immunodeficiency virus infection and congenital transmission of cytomegalovirus. *Pediatr Infect Dis J* (2010) 29(10): 915–8. doi: 10. 1097/INF. 0b013e3181e0ce05

29. Slyker JA, Lohman-Payne BL, Rowland-Jones SL, Otieno P, Maleche-Obimbo E, Richardson B, et al. The detection of cytomegalovirus DNA in maternal plasma is associated with mortality in HIV-1-infected women and their infants. *AIDS* (2009) 23(1): 117–24. doi: 10. 1097/QAD. 0b013e32831c8abd

30. Viljoen J, Tuaillon E, Nagot N, Danaviah S, Peries M, Padayachee P, et al. Cytomegalovirus, and possibly Epstein-Barr virus, shedding in breast milk is associated with HIV-1 transmission by breastfeeding. *AIDS* (2015) 29(2): 145–53. doi: 10. 1097/QAD. 0000000000000527

31. Chang T, Wiener J, Dollard S, Amin M, Ellington S, Chasela C, et al. Effect of cytomegalovirus infection on breastfeeding transmission of HIV and on the health of infants born to HIV-infected mothers. *AIDS* (2015) 29: 831–6. doi: 10. 1097/QAD. 0000000000000617

32. Slyker JA, Lohman-Payne BL, John-Stewart GC, Maleche-Obimbo E, Emery S, Richardson B, et al. Acute cytomegalovirus infection in Kenyan HIV-infected infants. *AIDS* (2009) 23(16): 2173–81. doi: 10. 1097/QAD. 0b013e32833016e8

33. Taipale A, Pelkonen T, Taipale M, Roine I, Bernardino L, Peltola H, et al. Otorhinolaryngological findings and hearing in HIV-positive and HIV-negative children in a developing country. *Eur Arch Otorhinolaryngol* (2011) 268(10): 1527–32. doi: 10. 1007/s00405-011-1579-x

34. Fasunla AJ, Ogunbosi BO, Odaibo GN, Nwaorgu OG, Taiwo B, Olaleye DO, et al. Comparison of auditory brainstem response in HIV-1 exposed and unexposed newborns and correlation with the maternal viral load and CD4+ cell counts. *AIDS* (2014) 28(15): 2223–30. doi: 10. 1097/QAD. 0000000000000393

35. Savva GM, Pachnio A, Kaul B, Morgan K, Huppert FA, Brayne C, et al. Cytomegalovirus infection is associated with increased mortality in the older population. *Aging Cell* (2013) 12(3): 381–7. doi: 10. 1111/acel. 12059

36. Wikby A, Johansson B, Olsson J, Lofgren S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. *Exp Gerontol* (2002) 37(2–3): 445–53. doi: 10. 1016/S0531-5565(01)00212-1

37. Schmaltz HN, Fried LP, Xue QL, Walston J, Leng SX, Semba RD. Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women. *J Am Geriatr Soc* (2005) 53(5): 747–54. doi: 10. 1111/j. 1532-5415. 2005. 53250. x

38. Derhovanessian E, Maier AB, Hahnel K, McElhaney JE, Slagboom EP, Pawelec G. Latent infection with cytomegalovirus is associated with poor memory CD4 responses to influenza A core proteins in the elderly. *J Immunol* (2014) 193(7): 3624–31. doi: 10. 4049/jimmunol. 1303361

39. Miles DJ, Sande M, Kaye S, Crozier S, Ojuola O, Palmero MS, et al. CD4(+) T cell responses to cytomegalovirus in early life: a prospective birth cohort study. *J Infect Dis* (2008) 197(5): 658–62. doi: 10. 1086/527418

40. Miles DJ, van der Sande M, Jeffries D, Kaye S, Ismaili J, Ojuola O, et al. Cytomegalovirus infection in Gambian infants leads to profound CD8 T-cell differentiation. *J Virol* (2007) 81(11): 5766–76. doi: 10. 1128/JVI. 00052-07

41. Miles DJ, van der Sande M, Jeffries D, Kaye S, Ojuola O, Sanneh M, et al. Maintenance of large subpopulations of differentiated CD8 T-cells two years after cytomegalovirus infection in Gambian infants. *PLoS One* (2008) 3(8): e2905. doi: 10. 1371/journal. pone. 0002905

42. Miles DJ, Sanneh M, Holder B, Crozier S, Nyamweya S, Touray ES, et al. Cytomegalovirus infection induces T-cell differentiation without impairing antigen-specific responses in Gambian infants. *Immunology* (2008) 124(3): 388–400. doi: 10. 1111/j. 1365-2567. 2007. 02787. x

43. Holder B, Miles DJ, Kaye S, Crozier S, Mohammed NI, Duah NO, et al. Epstein-Barr virus but not cytomegalovirus is associated with reduced vaccine antibody responses in Gambian infants. *PLoS One* (2010) 5(11): e14013. doi: 10. 1371/journal. pone. 0014013

44. Furman D, Jojic V, Sharma S, Shen-Orr SS, Angel CJ, Onengut-Gumuscu S, et al. Cytomegalovirus infection enhances the immune response to influenza. *Sci Transl Med* (2015) 7(281): 281ra43. doi: 10. 1126/scitranslmed. aaa2293

45. Nielsen CM, White MJ, Bottomley C, Lusa C, Rodriguez-Galan A, Turner SE, et al. Impaired NK cell responses to Pertussis and H1N1 influenza vaccine antigens in human cytomegalovirus-infected individuals. *J Immunol* (2015) 194(10): 4657–67. doi: 10. 4049/jimmunol. 1403080

46. Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling AC. Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. *JAMA* (2011) 305(6): 576–84. doi: 10. 1001/jama. 2011. 100

47. Sanz-Ramos M, Manno D, Kapambwe M, Ndumba I, Musonda KG, Bates M, et al. Reduced Poliovirus vaccine neutralising-antibody titres in infants with maternal HIV-exposure. *Vaccine* (2013) 31(16): 2042–9. doi: 10. 1016/j. vaccine. 2013. 02. 044

48. Adler SP, Chandrika T, Lawrence L, Baggett J. Cytomegalovirus infections in neonates acquired by blood transfusions. *Pediatr Infect Dis* (1983) 2(2): 114–8. doi: 10. 1097/00006454-198303000-00009

49. de Moraes-Pinto MI, Almeida AC, Kenj G, Filgueiras TE, Tobias W, Santos AM, et al. Placental transfer and maternally acquired neonatal IgG immunity in human immunodeficiency virus infection. *J Infect Dis* (1996) 173(5): 1077–84. doi: 10. 1093/infdis/173. 5. 1077

50. de Moraes-Pinto MI, Verhoeff F, Chimsuku L, Milligan PJ, Wesumperuma L, Broadhead RL, et al. Placental antibody transfer: influence of maternal HIV infection and placental malaria. *Arch Dis Child Fetal Neonatal Ed* (1998) 79(3): F202–5. doi: 10. 1136/fn. 79. 3. F202

51. Tabata T, Petitt M, Zydek M, Fang-Hoover J, Larocque N, Tsuge M, et al. Human cytomegalovirus infection interferes with the maintenance and differentiation of trophoblast progenitor cells of the human placenta. *J Virol* (2015) 89(9): 5134–47. doi: 10. 1128/JVI. 03674-14

52. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, et al. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. *J Infect Dis* (2011) 203(10): 1474–83. doi: 10. 1093/infdis/jir060

53. Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. *N Engl J Med* (2014) 370(14): 1316–26. doi: 10. 1056/NEJMoa1310214

54. Bialas KM, Permar SR. The March towards a vaccine for congenital CMV: rationale and models. *PLoS Pathog* (2016) 12(2): e1005355. doi: 10. 1371/journal. ppat. 1005355

55. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, et al. Vaccine prevention of maternal cytomegalovirus infection. *N Engl J Med* (2009) 360(12): 1191–9. doi: 10. 1056/NEJMoa0804749

56. Wussow F, Chiuppesi F, Martinez J, Campo J, Johnson E, Flechsig C, et al. Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. *PLoS Pathog* (2014) 10(11): e1004524. doi: 10. 1371/journal. ppat. 1004524

57. Lilleri D, Kabanova A, Revello MG, Percivalle E, Sarasini A, Genini E, et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. *PLoS One* (2013) 8(3): e59863. doi: 10. 1371/journal. pone. 0059863

58. Smith LR, Wloch MK, Chaplin JA, Gerber M, Rolland AP. Clinical development of a cytomegalovirus DNA vaccine: from product concept to pivotal phase 3 trial. *Vaccines (Basel)* (2013) 1(4): 398–414. doi: 10. 3390/vaccines1040398